Advertisement

Tipping the Balance from Angiogenesis to Fibrosis in Chronic Kidney Disease

  • Yosuke Hirakawa
  • Tetsuhiro Tanaka
  • Masaomi Nangaku
Chapter
Part of the Molecular and Translational Medicine book series (MOLEMED)

Abstract

The kidneys are innately under a low oxygen tension condition that originates from their unique and complicated vasculature. In chronic kidney disease (CKD), renal hypoxia occurs, and peritubular capillary rarefaction contributes to renal hypoxia. Interventions to angiogenic factors such as vascular endothelial growth factor (VEGF) and angiopoietin affect the development or maintenance of normal kidney structure. VEGF is mainly excreted from tubular cells and affects both endothelial cells and podocytes. Both low and high VEGF levels are injurious to the kidney; insufficient VEGF results in endothelial dysfunction, while excessive VEGF damages the glomeruli in a manner resembling diabetic kidney disease (DKD). The importance of angiopoietins is shown in atherosclerosis in CKD in both clinical patients and experimental animal models, while evidence of the effect of angiopoietins on CKD progression remains limited. Another important player is hypoxia. Clinical epidemiology findings have shown that renal hypoxia is involved in the pathogenesis and progression of CKD. Hypoxia-inducible factors (HIFs) govern the cellular response to hypoxia and have both angiogenetic and fibrogenic effects. The administration of VEGF, a HIF stabilizer, or progenitor cells leads to peritubular capillary maintenance, followed by renal fibrosis alleviation. Indoxyl sulfate is a representative uremic toxin and pathological factor that causes the imbalance between angiogenesis and fibrosis and subsequent insufficient HIF activation. The treatment of uremic toxins has the potential to adjust this angiogenesis–fibrosis imbalance.

Keywords

Chronic kidney disease Angiogenesis Fibrosis Hypoxia Hypoxia-inducible factor Vascular endothelial growth factor Angiopoietin 

References

  1. 1.
    Safran M, et al. Mouse model for noninvasive imaging of HIF prolyl hydroxylase activity: assessment of an oral agent that stimulates erythropoietin production. Proc Natl Acad Sci U S A. 2006;103:105–10.  https://doi.org/10.1073/pnas.0509459103.CrossRefPubMedGoogle Scholar
  2. 2.
    van Bommel J, Siegemund M, Henny C,P, Ince C. Heart, kidney, and intestine have different tolerances for anemia. Transl Res. 2008;151:110–7.  https://doi.org/10.1016/j.trsl.2007.11.001.CrossRefPubMedGoogle Scholar
  3. 3.
    Mimura I, Nangaku M. The suffocating kidney: tubulointerstitial hypoxia in end-stage renal disease. Nat Rev Nephrol. 2010;6:667–78.  https://doi.org/10.1038/nrneph.2010.124.CrossRefPubMedGoogle Scholar
  4. 4.
    Schurek HJ, Jost U, Baumgartl H, Bertram H, Heckmann U. Evidence for a preglomerular oxygen diffusion shunt in rat renal cortex. Am J Phys. 1990;259:F910–5.Google Scholar
  5. 5.
    Ngo JP, et al. Vascular geometry and oxygen diffusion in the vicinity of artery-vein pairs in the kidney. Am J Physiol Renal Physiol. 2014;307:F1111–22.  https://doi.org/10.1152/ajprenal.00382.2014.CrossRefPubMedGoogle Scholar
  6. 6.
    Olgac U, Kurtcuoglu V. Renal oxygenation: preglomerular vasculature is an unlikely contributor to renal oxygen shunting. Am J Physiol Renal Physiol. 2015;308:F671–88.  https://doi.org/10.1152/ajprenal.00551.2014.CrossRefPubMedGoogle Scholar
  7. 7.
    O’Neill J, et al. Acute SGLT inhibition normalizes O2 tension in the renal cortex but causes hypoxia in the renal medulla in anaesthetized control and diabetic rats. Am J Physiol Renal Physiol. 2015;309:F227–34.  https://doi.org/10.1152/ajprenal.00689.2014.CrossRefPubMedGoogle Scholar
  8. 8.
    Calzavacca P, et al. Long-term measurement of renal cortical and medullary tissue oxygenation and perfusion in unanesthetized sheep. Am J Physiol Regul Integr Comp Physiol. 2015;308:R832–9.  https://doi.org/10.1152/ajpregu.00515.2014.CrossRefPubMedGoogle Scholar
  9. 9.
    Harris DC, Chan L, Schrier RW. Remnant kidney hypermetabolism and progression of chronic renal failure. Am J Phys. 1988;254:F267–76.CrossRefGoogle Scholar
  10. 10.
    Deng A, et al. Renal protection in chronic kidney disease: hypoxia-inducible factor activation vs. angiotensin II blockade. Am J Physiol Renal Physiol. 2010;299:F1365–73.  https://doi.org/10.1152/ajprenal.00153.2010.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Adler S, Huang H. Impaired regulation of renal oxygen consumption in spontaneously hypertensive rats. J Am Soc Nephrol. 2002;13:1788–94.CrossRefGoogle Scholar
  12. 12.
    Korner A, Eklof AC, Celsi G, Aperia A. Increased renal metabolism in diabetes. Mechanism and functional implications. Diabetes. 1994;43:629–33.CrossRefGoogle Scholar
  13. 13.
    Nangaku M. Chronic hypoxia and tubulointerstitial injury: a final common pathway to end-stage renal failure. J Am Soc Nephrol. 2006;17:17–25.  https://doi.org/10.1681/asn.2005070757.CrossRefPubMedGoogle Scholar
  14. 14.
    Lindenmeyer MT, et al. Interstitial vascular rarefaction and reduced VEGF-A expression in human diabetic nephropathy. J Am Soc Nephrol. 2007;18:1765–76.  https://doi.org/10.1681/asn.2006121304.CrossRefPubMedGoogle Scholar
  15. 15.
    Kaukinen A, Lautenschlager I, Helin H, Karikoski R, Jalanko H. Peritubular capillaries are rarefied in congenital nephrotic syndrome of the Finnish type. Kidney Int. 2009;75:1099–108.  https://doi.org/10.1038/ki.2009.41.CrossRefPubMedGoogle Scholar
  16. 16.
    Yuan HT, Li XZ, Pitera JE, Long DA, Woolf AS. Peritubular capillary loss after mouse acute nephrotoxicity correlates with down-regulation of vascular endothelial growth factor-A and hypoxia-inducible factor-1 alpha. Am J Pathol. 2003;163:2289–301.CrossRefGoogle Scholar
  17. 17.
    Ohashi R, et al. Peritubular capillary regression during the progression of experimental obstructive nephropathy. J Am Soc Nephrol. 2002;13:1795–805.CrossRefGoogle Scholar
  18. 18.
    Kang DH, et al. Impaired angiogenesis in the remnant kidney model: I. Potential role of vascular endothelial growth factor and thrombospondin-1. J Am Soc Nephrol. 2001;12:1434–47.PubMedGoogle Scholar
  19. 19.
    Futatsugi K, et al. Obesity-induced kidney injury is attenuated by amelioration of aberrant PHD2 activation in proximal tubules. Sci Rep. 2016;6:36533.  https://doi.org/10.1038/srep36533.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Tanaka S, Tanaka T, Nangaku M. Hypoxia as a key player in the AKI-to-CKD transition. Am J Physiol Renal Physiol. 2014;307:F1187–95.  https://doi.org/10.1152/ajprenal.00425.2014.CrossRefPubMedGoogle Scholar
  21. 21.
    Kramann R, Tanaka M, Humphreys BD. Fluorescence microangiography for quantitative assessment of peritubular capillary changes after AKI in mice. J Am Soc Nephrol. 2014;25:1924–31.  https://doi.org/10.1681/asn.2013101121.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Neufeld G, Cohen T, Gengrinovitch S, Poltorak Z. Vascular endothelial growth factor (VEGF) and its receptors. FASEB J. 1999;13:9–22.CrossRefGoogle Scholar
  23. 23.
    Tanaka T, Nangaku M. Angiogenesis and hypoxia in the kidney. Nat Rev Nephrol. 2013;9:211–22.  https://doi.org/10.1038/nrneph.2013.35.CrossRefPubMedGoogle Scholar
  24. 24.
    Simon M, et al. Expression of vascular endothelial growth factor and its receptors in human renal ontogenesis and in adult kidney. Am J Phys. 1995;268:F240–50.Google Scholar
  25. 25.
    Brown LF, et al. Vascular permeability factor mRNA and protein expression in human kidney. Kidney Int. 1992;42:1457–61.CrossRefGoogle Scholar
  26. 26.
    Simon M, et al. Receptors of vascular endothelial growth factor/vascular permeability factor (VEGF/VPF) in fetal and adult human kidney: localization and [125I]VEGF binding sites. J Am Soc Nephrol. 1998;9:1032–44.PubMedGoogle Scholar
  27. 27.
    Summers AM, et al. VEGF -460 genotype plays an important role in progression to chronic kidney disease stage 5. Nephrol Dial Transplant. 2005;20:2427–32.  https://doi.org/10.1093/ndt/gfi029.CrossRefPubMedGoogle Scholar
  28. 28.
    Donderski R, et al. Analysis of relative expression level of VEGF ( vascular endothelial growth factor ), HIF-1alpha ( hypoxia inducible factor 1alpha ) and CTGF ( connective tissue growth factor ) genes in chronic glomerulonephritis (CGN) patients. Kidney Blood Press Res. 2013;38:83–91.  https://doi.org/10.1159/000355754.CrossRefPubMedGoogle Scholar
  29. 29.
    Chen YT, et al. Value and level of circulating endothelial progenitor cells, angiogenesis factors and mononuclear cell apoptosis in patients with chronic kidney disease. Clin Exp Nephrol. 2013;17:83–91.  https://doi.org/10.1007/s10157-012-0664-9.CrossRefPubMedGoogle Scholar
  30. 30.
    Hohenstein B, et al. Local VEGF activity but not VEGF expression is tightly regulated during diabetic nephropathy in man. Kidney Int. 2006;69:1654–61.  https://doi.org/10.1038/sj.ki.5000294.CrossRefPubMedGoogle Scholar
  31. 31.
    Foster RR, et al. Functional evidence that vascular endothelial growth factor may act as an autocrine factor on human podocytes. Am J Physiol Renal Physiol. 2003;284:F1263–73.  https://doi.org/10.1152/ajprenal.00276.2002.CrossRefPubMedGoogle Scholar
  32. 32.
    Ku CH, et al. Inducible overexpression of sFlt-1 in podocytes ameliorates glomerulopathy in diabetic mice. Diabetes. 2008;57:2824–33.  https://doi.org/10.2337/db08-0647.CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Kosugi T, et al. Soluble Flt-1 gene therapy ameliorates albuminuria but accelerates tubulointerstitial injury in diabetic mice. Am J Physiol Renal Physiol. 2010;298:F609–16.  https://doi.org/10.1152/ajprenal.00377.2009.CrossRefPubMedGoogle Scholar
  34. 34.
    Oltean S, et al. Vascular endothelial growth factor-A165b is protective and restores endothelial glycocalyx in diabetic nephropathy. J Am Soc Nephrol. 2015;26:1889–904.  https://doi.org/10.1681/asn.2014040350.CrossRefPubMedGoogle Scholar
  35. 35.
    Ferrara N, et al. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature. 1996;380:439–42.  https://doi.org/10.1038/380439a0.CrossRefPubMedGoogle Scholar
  36. 36.
    Carmeliet P, et al. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature. 1996;380:435–9.  https://doi.org/10.1038/380435a0.CrossRefPubMedGoogle Scholar
  37. 37.
    Eremina V, et al. VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med. 2008;358:1129–36.  https://doi.org/10.1056/NEJMoa0707330.CrossRefPubMedPubMedCentralGoogle Scholar
  38. 38.
    Izzedine H, et al. Kidney diseases associated with anti-vascular endothelial growth factor (VEGF): an 8-year observational study at a single center. Medicine (Baltimore). 2014;93:333–9.  https://doi.org/10.1097/md.0000000000000207.CrossRefGoogle Scholar
  39. 39.
    Vigneau C, et al. All anti-vascular endothelial growth factor drugs can induce ‘pre-eclampsia-like syndrome’: a RARe study. Nephrol Dial Transplant. 2014;29:325–32.  https://doi.org/10.1093/ndt/gft465.CrossRefPubMedGoogle Scholar
  40. 40.
    Izzedine H, et al. Expression patterns of RelA and c-mip are associated with different glomerular diseases following anti-VEGF therapy. Kidney Int. 2014;85:457–70.  https://doi.org/10.1038/ki.2013.344.CrossRefPubMedGoogle Scholar
  41. 41.
    Eremina V, et al. Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases. J Clin Invest. 2003;111:707–16.  https://doi.org/10.1172/jci17423.CrossRefPubMedPubMedCentralGoogle Scholar
  42. 42.
    Veron D, et al. Acute podocyte vascular endothelial growth factor (VEGF-A) knockdown disrupts alphaVbeta3 integrin signaling in the glomerulus. PLoS One. 2012;7:e40589.  https://doi.org/10.1371/journal.pone.0040589.CrossRefPubMedPubMedCentralGoogle Scholar
  43. 43.
    Liu E, et al. Increased expression of vascular endothelial growth factor in kidney leads to progressive impairment of glomerular functions. J Am Soc Nephrol. 2007;18:2094–104.  https://doi.org/10.1681/asn.2006010075.CrossRefPubMedGoogle Scholar
  44. 44.
    Sato W, et al. Selective stimulation of VEGFR2 accelerates progressive renal disease. Am J Pathol. 2011;179:155–66.  https://doi.org/10.1016/j.ajpath.2011.03.024.CrossRefPubMedPubMedCentralGoogle Scholar
  45. 45.
    Veron D, et al. Overexpression of VEGF-A in podocytes of adult mice causes glomerular disease. Kidney Int. 2010;77:989–99.  https://doi.org/10.1038/ki.2010.64.CrossRefPubMedGoogle Scholar
  46. 46.
    Veron D, et al. Podocyte-specific VEGF-a gain of function induces nodular glomerulosclerosis in eNOS null mice. J Am Soc Nephrol. 2014;25:1814–24.  https://doi.org/10.1681/asn.2013070752.CrossRefPubMedPubMedCentralGoogle Scholar
  47. 47.
    Ma J, et al. Induction of podocyte-derived VEGF ameliorates podocyte injury and subsequent abnormal glomerular development caused by puromycin aminonucleoside. Pediatr Res. 2011;70:83–9.  https://doi.org/10.1203/PDR.0b013e31821bdf1c.CrossRefPubMedPubMedCentralGoogle Scholar
  48. 48.
    Hakroush S, et al. Effects of increased renal tubular vascular endothelial growth factor (VEGF) on fibrosis, cyst formation, and glomerular disease. Am J Pathol. 2009;175:1883–95.  https://doi.org/10.2353/ajpath.2009.080792.CrossRefPubMedPubMedCentralGoogle Scholar
  49. 49.
    Di Marco GS, et al. The soluble VEGF receptor sFlt1 contributes to endothelial dysfunction in CKD. J Am Soc Nephrol. 2009;20:2235–45.  https://doi.org/10.1681/asn.2009010061.CrossRefPubMedPubMedCentralGoogle Scholar
  50. 50.
    Hara A, et al. Blockade of VEGF accelerates proteinuria, via decrease in nephrin expression in rat crescentic glomerulonephritis. Kidney Int. 2006;69:1986–95.  https://doi.org/10.1038/sj.ki.5000439.CrossRefPubMedGoogle Scholar
  51. 51.
    Jin J, et al. Soluble FLT1 binds lipid microdomains in podocytes to control cell morphology and glomerular barrier function. Cell. 2012;151:384–99.  https://doi.org/10.1016/j.cell.2012.08.037.CrossRefPubMedGoogle Scholar
  52. 52.
    Maynard SE, et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest. 2003;111:649–58.  https://doi.org/10.1172/jci17189.CrossRefPubMedPubMedCentralGoogle Scholar
  53. 53.
    Levine RJ, et al. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med. 2004;350:672–83.  https://doi.org/10.1056/NEJMoa031884.CrossRefPubMedGoogle Scholar
  54. 54.
    Onoue K, et al. Reduction of circulating soluble fms-like tyrosine kinase-1 plays a significant role in renal dysfunction-associated aggravation of atherosclerosis. Circulation. 2009;120:2470–7.  https://doi.org/10.1161/circulationaha.109.867929.CrossRefPubMedGoogle Scholar
  55. 55.
    Matsui M, et al. Suppressed soluble Fms-like tyrosine kinase-1 production aggravates atherosclerosis in chronic kidney disease. Kidney Int. 2014;85:393–403.  https://doi.org/10.1038/ki.2013.339.CrossRefPubMedGoogle Scholar
  56. 56.
    Augustin HG, Koh GY, Thurston G, Alitalo K. Control of vascular morphogenesis and homeostasis through the angiopoietin-Tie system. Nat Rev Mol Cell Biol. 2009;10:165–77.  https://doi.org/10.1038/nrm2639.CrossRefPubMedGoogle Scholar
  57. 57.
    Oh H, et al. Hypoxia and vascular endothelial growth factor selectively up-regulate angiopoietin-2 in bovine microvascular endothelial cells. J Biol Chem. 1999;274:15732–9.CrossRefGoogle Scholar
  58. 58.
    Saharinen P, et al. Angiopoietins assemble distinct Tie2 signalling complexes in endothelial cell-cell and cell-matrix contacts. Nat Cell Biol. 2008;10:527–37.  https://doi.org/10.1038/ncb1715.CrossRefPubMedGoogle Scholar
  59. 59.
    David S, et al. Angiopoietin 2 and cardiovascular disease in dialysis and kidney transplantation. Am J Kidney Dis. 2009;53:770–8.  https://doi.org/10.1053/j.ajkd.2008.11.030.CrossRefPubMedGoogle Scholar
  60. 60.
    David S, et al. Circulating angiopoietin-2 levels increase with progress of chronic kidney disease. Nephrol Dial Transplant. 2010;25:2571–6.  https://doi.org/10.1093/ndt/gfq060.CrossRefPubMedGoogle Scholar
  61. 61.
    David S, et al. Angiopoietin-2 levels predict mortality in CKD patients. Nephrol Dial Transplant. 2012;27:1867–72.  https://doi.org/10.1093/ndt/gfr551.CrossRefPubMedGoogle Scholar
  62. 62.
    Chang FC, et al. Angiopoietin-2 is associated with albuminuria and microinflammation in chronic kidney disease. PLoS One. 2013;8:e54668.  https://doi.org/10.1371/journal.pone.0054668.CrossRefPubMedPubMedCentralGoogle Scholar
  63. 63.
    Tsai YC, et al. Association of angiopoietin-2 with renal outcome in chronic kidney disease. PLoS One. 2014;9:e108862.  https://doi.org/10.1371/journal.pone.0108862.CrossRefPubMedPubMedCentralGoogle Scholar
  64. 64.
    Tsai YC, et al. Angiopoietin-2, angiopoietin-1 and subclinical cardiovascular disease in chronic kidney disease. Sci Rep. 2016;6:39400.  https://doi.org/10.1038/srep39400.CrossRefPubMedPubMedCentralGoogle Scholar
  65. 65.
    Fujisawa T, et al. Angiopoietin-1 promotes atherosclerosis by increasing the proportion of circulating Gr1+ monocytes. Cardiovasc Res. 2017;113:81–9.  https://doi.org/10.1093/cvr/cvw223.CrossRefPubMedPubMedCentralGoogle Scholar
  66. 66.
    Yuan HT, Tipping PG, Li XZ, Long DA, Woolf AS. Angiopoietin correlates with glomerular capillary loss in anti-glomerular basement membrane glomerulonephritis. Kidney Int. 2002;61:2078–89.  https://doi.org/10.1046/j.1523-1755.2002.00381.x.CrossRefPubMedGoogle Scholar
  67. 67.
    Kim W, et al. COMP-angiopoietin-1 ameliorates renal fibrosis in a unilateral ureteral obstruction model. J Am Soc Nephrol. 2006;17:2474–83.  https://doi.org/10.1681/asn.2006020109.CrossRefPubMedGoogle Scholar
  68. 68.
    Dessapt-Baradez C, et al. Targeted glomerular angiopoietin-1 therapy for early diabetic kidney disease. J Am Soc Nephrol. 2014;25:33–42.  https://doi.org/10.1681/asn.2012121218.CrossRefPubMedGoogle Scholar
  69. 69.
    Singh S, et al. Tubular overexpression of angiopoietin-1 attenuates renal fibrosis. PLoS One. 2016;11:e0158908.  https://doi.org/10.1371/journal.pone.0158908.CrossRefPubMedPubMedCentralGoogle Scholar
  70. 70.
    Long DA, et al. Angiopoietin-1 therapy enhances fibrosis and inflammation following folic acid-induced acute renal injury. Kidney Int. 2008;74:300–9.  https://doi.org/10.1038/ki.2008.179.CrossRefPubMedGoogle Scholar
  71. 71.
    Ahmed A, et al. Angiopoietin-2 confers atheroprotection in apoE-/- mice by inhibiting LDL oxidation via nitric oxide. Circ Res. 2009;104:1333–6.  https://doi.org/10.1161/circresaha.109.196154.CrossRefPubMedPubMedCentralGoogle Scholar
  72. 72.
    Theelen TL, et al. Angiopoietin-2 blocking antibodies reduce early atherosclerotic plaque development in mice. Atherosclerosis. 2015;241:297–304.  https://doi.org/10.1016/j.atherosclerosis.2015.05.018.CrossRefPubMedPubMedCentralGoogle Scholar
  73. 73.
    Chang FC, et al. Angiopoietin-2-induced arterial stiffness in CKD. J Am Soc Nephrol. 2014;25:1198–209.  https://doi.org/10.1681/asn.2013050542.CrossRefPubMedPubMedCentralGoogle Scholar
  74. 74.
    Hu J, et al. Endothelial cell-derived angiopoietin-2 controls liver regeneration as a spatiotemporal rheostat. Science. 2014;343:416–9.  https://doi.org/10.1126/science.1244880.CrossRefPubMedGoogle Scholar
  75. 75.
    Venkatesha S, et al. Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat Med. 2006;12:642–9.  https://doi.org/10.1038/nm1429.CrossRefPubMedGoogle Scholar
  76. 76.
    Leanos-Miranda A, Campos-Galicia I, Ramirez-Valenzuela KL, Chinolla-Arellano ZL, Isordia-Salas I. Circulating angiogenic factors and urinary prolactin as predictors of adverse outcomes in women with preeclampsia. Hypertension. 2013;61:1118–25.  https://doi.org/10.1161/hypertensionaha.111.00754.CrossRefPubMedGoogle Scholar
  77. 77.
    Shen F, et al. Endoglin deficiency impairs stroke recovery. Stroke. 2014;45:2101–6.  https://doi.org/10.1161/strokeaha.114.005115.CrossRefPubMedPubMedCentralGoogle Scholar
  78. 78.
    Kapur NK, et al. Reducing endoglin activity limits calcineurin and TRPC-6 expression and improves survival in a mouse model of right ventricular pressure overload. J Am Heart Assoc. 2014;3:e000965.  https://doi.org/10.1161/jaha.114.000965.CrossRefPubMedPubMedCentralGoogle Scholar
  79. 79.
    Ojeda-Fernandez L, et al. Mice lacking endoglin in macrophages show an impaired immune response. PLoS Genet. 2016;12:e1005935.  https://doi.org/10.1371/journal.pgen.1005935.CrossRefPubMedPubMedCentralGoogle Scholar
  80. 80.
    Charytan DM, et al. Circulating endoglin concentration is not elevated in chronic kidney disease. PLoS One. 2011;6:e23718.  https://doi.org/10.1371/journal.pone.0023718.CrossRefPubMedPubMedCentralGoogle Scholar
  81. 81.
    Docherty NG, et al. Endoglin regulates renal ischaemia-reperfusion injury. Nephrol Dial Transplant. 2006;21:2106–19.  https://doi.org/10.1093/ndt/gfl179.CrossRefPubMedGoogle Scholar
  82. 82.
    Oujo B, et al. L-Endoglin overexpression increases renal fibrosis after unilateral ureteral obstruction. PLoS One. 2014;9:e110365.  https://doi.org/10.1371/journal.pone.0110365.CrossRefPubMedPubMedCentralGoogle Scholar
  83. 83.
    Munoz-Felix JM, et al. Overexpression of the short endoglin isoform reduces renal fibrosis and inflammation after unilateral ureteral obstruction. Biochim Biophys Acta. 2016;1862:1801–14.  https://doi.org/10.1016/j.bbadis.2016.06.010.CrossRefPubMedGoogle Scholar
  84. 84.
    Siebert J, et al. Low serum angiogenin concentrations in patients with type 2 diabetes. Diabetes Care. 2007;30:3086–7.  https://doi.org/10.2337/dc07-0629.CrossRefPubMedGoogle Scholar
  85. 85.
    Nakamura M, et al. Hypoxic conditions stimulate the production of angiogenin and vascular endothelial growth factor by human renal proximal tubular epithelial cells in culture. Nephrol Dial Transplant. 2006;21:1489–95.  https://doi.org/10.1093/ndt/gfl041.CrossRefPubMedGoogle Scholar
  86. 86.
    Tavernier Q, et al. Urinary angiogenin reflects the magnitude of kidney injury at the infrahistologic level. J Am Soc Nephrol. 2017;28:678–90.  https://doi.org/10.1681/asn.2016020218.CrossRefPubMedGoogle Scholar
  87. 87.
    Mami I, et al. Angiogenin mediates cell-autonomous translational control under endoplasmic reticulum stress and attenuates kidney injury. J Am Soc Nephrol. 2016;27:863–76.  https://doi.org/10.1681/asn.2015020196.CrossRefPubMedGoogle Scholar
  88. 88.
    Saxena SK, Rybak SM, Davey RT Jr, Youle RJ, Ackerman EJ. Angiogenin is a cytotoxic, tRNA-specific ribonuclease in the RNase A superfamily. J Biol Chem. 1992;267:21982–6.PubMedGoogle Scholar
  89. 89.
    Crawford SE, et al. Thrombospondin-1 is a major activator of TGF-beta1 in vivo. Cell. 1998;93:1159–70.CrossRefGoogle Scholar
  90. 90.
    Bige N, et al. Thrombospondin-1 plays a profibrotic and pro-inflammatory role during ureteric obstruction. Kidney Int. 2012;81:1226–38.  https://doi.org/10.1038/ki.2012.21.CrossRefPubMedGoogle Scholar
  91. 91.
    Cui W, Maimaitiyiming H, Qi X, Norman H, Wang S. Thrombospondin 1 mediates renal dysfunction in a mouse model of high-fat diet-induced obesity. Am J Physiol Renal Physiol. 2013;305:F871–80.  https://doi.org/10.1152/ajprenal.00209.2013.CrossRefPubMedPubMedCentralGoogle Scholar
  92. 92.
    Zeisberg M, et al. Thrombospondin-1 deficiency causes a shift from fibroproliferative to inflammatory kidney disease and delays onset of renal failure. Am J Pathol. 2014;184:2687–98.  https://doi.org/10.1016/j.ajpath.2014.06.014.CrossRefPubMedPubMedCentralGoogle Scholar
  93. 93.
    Maimaitiyiming H, Zhou Q, Wang S. Thrombospondin 1 deficiency ameliorates the development of adriamycin-induced proteinuric kidney disease. PLoS One. 2016;11:e0156144.  https://doi.org/10.1371/journal.pone.0156144.CrossRefPubMedPubMedCentralGoogle Scholar
  94. 94.
    Maimaitiyiming H, Clemons K, Zhou Q, Norman H, Wang S. Thrombospondin1 deficiency attenuates obesity-associated microvascular complications in ApoE-/- mice. PLoS One. 2015;10:e0121403.  https://doi.org/10.1371/journal.pone.0121403.CrossRefPubMedPubMedCentralGoogle Scholar
  95. 95.
    Yao M, et al. Thrombospondin-1 activation of signal-regulatory protein-alpha stimulates reactive oxygen species production and promotes renal ischemia reperfusion injury. J Am Soc Nephrol. 2014;25:1171–86.  https://doi.org/10.1681/asn.2013040433.CrossRefPubMedPubMedCentralGoogle Scholar
  96. 96.
    Sun D, et al. Thrombospondin-1 short hairpin RNA suppresses tubulointerstitial fibrosis in the kidney of ureteral obstruction by ameliorating peritubular capillary injury. Kidney Blood Press Res. 2012;35:35–47.  https://doi.org/10.1159/000330718.CrossRefPubMedGoogle Scholar
  97. 97.
    Hirakawa Y, et al. Quantitating intracellular oxygen tension in vivo by phosphorescence lifetime measurement. Sci Rep. 2015;5:17838.  https://doi.org/10.1038/srep17838.CrossRefPubMedPubMedCentralGoogle Scholar
  98. 98.
    Tsubakihara Y, et al. High target hemoglobin with erythropoiesis-stimulating agents has advantages in the renal function of non-dialysis chronic kidney disease patients. Ther Apher Dial. 2012;16:529–40.  https://doi.org/10.1111/j.1744-9987.2012.01082.x.CrossRefPubMedGoogle Scholar
  99. 99.
    Palmer SC, et al. Meta-analysis: erythropoiesis-stimulating agents in patients with chronic kidney disease. Ann Intern Med. 2010;153:23–33.  https://doi.org/10.7326/0003-4819-153-1-201007060-00252.CrossRefPubMedGoogle Scholar
  100. 100.
    Mimura I, Tanaka T, Nangaku M. How the target hemoglobin of renal anemia should be. Nephron. 2015;131:202–9.  https://doi.org/10.1159/000440849.CrossRefPubMedGoogle Scholar
  101. 101.
    Gouva C, Nikolopoulos P, Ioannidis JP, Siamopoulos KC. Treating anemia early in renal failure patients slows the decline of renal function: a randomized controlled trial. Kidney Int. 2004;66:753–60.  https://doi.org/10.1111/j.1523-1755.2004.00797.x.CrossRefPubMedGoogle Scholar
  102. 102.
    Akizawa T, et al. A prospective observational study of early intervention with erythropoietin therapy and renal survival in non-dialysis chronic kidney disease patients with anemia: JET-STREAM study. Clin Exp Nephrol. 2016;20:885–95.  https://doi.org/10.1007/s10157-015-1225-9.CrossRefPubMedPubMedCentralGoogle Scholar
  103. 103.
    Brines M, et al. Erythropoietin mediates tissue protection through an erythropoietin and common beta-subunit heteroreceptor. Proc Natl Acad Sci U S A. 2004;101:14907–12.  https://doi.org/10.1073/pnas.0406491101.CrossRefPubMedPubMedCentralGoogle Scholar
  104. 104.
    Luks AM, Johnson RJ, Swenson ER. Chronic kidney disease at high altitude. J Am Soc Nephrol. 2008;19:2262–71.  https://doi.org/10.1681/asn.2007111199.CrossRefPubMedGoogle Scholar
  105. 105.
    Chen W, et al. Prevalence and risk factors of chronic kidney disease: a population study in the Tibetan population. Nephrol Dial Transplant. 2011;26:1592–9.  https://doi.org/10.1093/ndt/gfq608.CrossRefPubMedGoogle Scholar
  106. 106.
    Nicholl DD, et al. Declining kidney function increases the prevalence of sleep apnea and nocturnal hypoxia. Chest. 2012;141:1422–30.  https://doi.org/10.1378/chest.11-1809.CrossRefPubMedGoogle Scholar
  107. 107.
    Iseki K, Tohyama K, Matsumoto T, Nakamura H. High prevalence of chronic kidney disease among patients with sleep related breathing disorder (SRBD). Hypertens Res. 2008;31:249–55.  https://doi.org/10.1291/hypres.31.249.CrossRefPubMedGoogle Scholar
  108. 108.
    Chen CY, Liao KM. Chronic obstructive pulmonary disease is associated with risk of chronic kidney disease: a nationwide case-cohort study. Sci Rep. 2016;6:25855.  https://doi.org/10.1038/srep25855.CrossRefPubMedPubMedCentralGoogle Scholar
  109. 109.
    Prasad PV, Edelman RR, Epstein FH. Noninvasive evaluation of intrarenal oxygenation with BOLD MRI. Circulation. 1996;94:3271–5.CrossRefGoogle Scholar
  110. 110.
    Inoue T, et al. Noninvasive evaluation of kidney hypoxia and fibrosis using magnetic resonance imaging. J Am Soc Nephrol. 2011;22:1429–34.  https://doi.org/10.1681/asn.2010111143.CrossRefPubMedPubMedCentralGoogle Scholar
  111. 111.
    Michaely HJ, et al. Renal BOLD-MRI does not reflect renal function in chronic kidney disease. Kidney Int. 2012;81:684–9.  https://doi.org/10.1038/ki.2011.455.CrossRefPubMedGoogle Scholar
  112. 112.
    Khatir DS, Pedersen M, Jespersen B, Buus NH. Evaluation of renal blood flow and oxygenation in CKD using magnetic resonance imaging. Am J Kidney Dis. 2015;66:402–11.  https://doi.org/10.1053/j.ajkd.2014.11.022.CrossRefPubMedGoogle Scholar
  113. 113.
    Pruijm M, et al. Determinants of renal tissue oxygenation as measured with BOLD-MRI in chronic kidney disease and hypertension in humans. PLoS One. 2014;9:e95895.  https://doi.org/10.1371/journal.pone.0095895.CrossRefPubMedPubMedCentralGoogle Scholar
  114. 114.
    Piskunowicz M, et al. A new technique with high reproducibility to estimate renal oxygenation using BOLD-MRI in chronic kidney disease. Magn Reson Imaging. 2015;33:253–61.  https://doi.org/10.1016/j.mri.2014.12.002.CrossRefPubMedGoogle Scholar
  115. 115.
    Milani B, et al. Reduction of cortical oxygenation in chronic kidney disease: evidence obtained with a new analysis method of blood oxygenation level-dependent magnetic resonance imaging. Nephrol Dial Transplant. 2016;  https://doi.org/10.1093/ndt/gfw362.
  116. 116.
    Pruijm M, Milani B, Burnier M. Blood oxygenation level-dependent MRI to assess renal oxygenation in renal diseases: progresses and challenges. Front Physiol. 2016;7:667.  https://doi.org/10.3389/fphys.2016.00667.CrossRefPubMedGoogle Scholar
  117. 117.
    Semenza GL, Wang GL. A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation. Mol Cell Biol. 1992;12:5447–54.CrossRefGoogle Scholar
  118. 118.
    Rosenberger C, et al. Expression of hypoxia-inducible factor-1alpha and -2alpha in hypoxic and ischemic rat kidneys. J Am Soc Nephrol. 2002;13:1721–32.CrossRefGoogle Scholar
  119. 119.
    Manotham K, et al. A biologic role of HIF-1 in the renal medulla. Kidney Int. 2005;67:1428–39.  https://doi.org/10.1111/j.1523-1755.2005.00220.x.CrossRefPubMedGoogle Scholar
  120. 120.
    Mimura I, et al. Dynamic change of chromatin conformation in response to hypoxia enhances the expression of GLUT3 (SLC2A3) by cooperative interaction of hypoxia-inducible factor 1 and KDM3A. Mol Cell Biol. 2012;32:3018–32.  https://doi.org/10.1128/mcb.06643-11.CrossRefPubMedPubMedCentralGoogle Scholar
  121. 121.
    Nordquist L, et al. Activation of hypoxia-inducible factors prevents diabetic nephropathy. J Am Soc Nephrol. 2015;26:328–38.  https://doi.org/10.1681/asn.2013090990.CrossRefPubMedGoogle Scholar
  122. 122.
    Tanaka T, et al. Induction of protective genes by cobalt ameliorates tubulointerstitial injury in the progressive Thy1 nephritis. Kidney Int. 2005;68:2714–25.  https://doi.org/10.1111/j.1523-1755.2005.00742.x.CrossRefPubMedGoogle Scholar
  123. 123.
    Mack M, Yanagita M. Origin of myofibroblasts and cellular events triggering fibrosis. Kidney Int. 2015;87:297–307.  https://doi.org/10.1038/ki.2014.287.CrossRefPubMedGoogle Scholar
  124. 124.
    Yamazaki S, et al. A mouse model of adult-onset anaemia due to erythropoietin deficiency. Nat Commun. 2013;4:1950.  https://doi.org/10.1038/ncomms2950.CrossRefPubMedGoogle Scholar
  125. 125.
    Souma T, et al. Plasticity of renal erythropoietin-producing cells governs fibrosis. J Am Soc Nephrol. 2013;24:1599–616.  https://doi.org/10.1681/asn.2013010030.CrossRefPubMedPubMedCentralGoogle Scholar
  126. 126.
    Souma T, et al. Erythropoietin synthesis in renal myofibroblasts is restored by activation of hypoxia signaling. J Am Soc Nephrol. 2016;27:428–38.  https://doi.org/10.1681/asn.2014121184.CrossRefPubMedGoogle Scholar
  127. 127.
    Kawakami T, Mimura I, Shoji K, Tanaka T, Nangaku M. Kidney Int Suppl (2011). 2014;4:107–12.CrossRefGoogle Scholar
  128. 128.
    Humphreys BD, et al. Fate tracing reveals the pericyte and not epithelial origin of myofibroblasts in kidney fibrosis. Am J Pathol. 2010;176:85–97.  https://doi.org/10.2353/ajpath.2010.090517.CrossRefPubMedPubMedCentralGoogle Scholar
  129. 129.
    Gomez IG, et al. TWEAK-Fn14 signaling activates myofibroblasts to drive progression of fibrotic kidney disease. J Am Soc Nephrol. 2016;27:3639–52.  https://doi.org/10.1681/asn.2015111227.CrossRefPubMedPubMedCentralGoogle Scholar
  130. 130.
    Lin SL, et al. Targeting endothelium-pericyte cross talk by inhibiting VEGF receptor signaling attenuates kidney microvascular rarefaction and fibrosis. Am J Pathol. 2011;178:911–23.  https://doi.org/10.1016/j.ajpath.2010.10.012.CrossRefPubMedPubMedCentralGoogle Scholar
  131. 131.
    Leaf IA, et al. Pericyte MyD88 and IRAK4 control inflammatory and fibrotic responses to tissue injury. J Clin Invest. 2017;127:321–34.  https://doi.org/10.1172/jci87532.CrossRefPubMedGoogle Scholar
  132. 132.
    Schrimpf C, et al. Pericyte TIMP3 and ADAMTS1 modulate vascular stability after kidney injury. J Am Soc Nephrol. 2012;23:868–83.  https://doi.org/10.1681/asn.2011080851.CrossRefPubMedPubMedCentralGoogle Scholar
  133. 133.
    Kramann R, Wongboonsin J, Chang-Panesso M, Machado FG, Humphreys BD. Gli1+ pericyte loss induces capillary rarefaction and proximal tubular injury. J Am Soc Nephrol. 2017;28:776–84.  https://doi.org/10.1681/asn.2016030297.CrossRefPubMedGoogle Scholar
  134. 134.
    Manotham K, et al. Transdifferentiation of cultured tubular cells induced by hypoxia. Kidney Int. 2004;65:871–80.  https://doi.org/10.1111/j.1523-1755.2004.00461.x.CrossRefPubMedGoogle Scholar
  135. 135.
    Lovisa S, et al. Epithelial-to-mesenchymal transition induces cell cycle arrest and parenchymal damage in renal fibrosis. Nat Med. 2015;21:998–1009.  https://doi.org/10.1038/nm.3902.CrossRefPubMedPubMedCentralGoogle Scholar
  136. 136.
    Grande MT, et al. Snail1-induced partial epithelial-to-mesenchymal transition drives renal fibrosis in mice and can be targeted to reverse established disease. Nat Med. 2015;21:989–97.  https://doi.org/10.1038/nm.3901.CrossRefPubMedGoogle Scholar
  137. 137.
    Sun S, et al. Hypoxia-inducible factor-1alpha induces Twist expression in tubular epithelial cells subjected to hypoxia, leading to epithelial-to-mesenchymal transition. Kidney Int. 2009;75:1278–87.  https://doi.org/10.1038/ki.2009.62.CrossRefPubMedGoogle Scholar
  138. 138.
    Du R, et al. Hypoxia-induced down-regulation of microRNA-34a promotes EMT by targeting the Notch signaling pathway in tubular epithelial cells. PLoS One. 2012;7:e30771.  https://doi.org/10.1371/journal.pone.0030771.CrossRefPubMedPubMedCentralGoogle Scholar
  139. 139.
    LeBleu VS, et al. Origin and function of myofibroblasts in kidney fibrosis. Nat Med. 2013;19:1047–53.  https://doi.org/10.1038/nm.3218.CrossRefPubMedPubMedCentralGoogle Scholar
  140. 140.
    Kang DH, Hughes J, Mazzali M, Schreiner GF, Johnson RJ. Impaired angiogenesis in the remnant kidney model: II. Vascular endothelial growth factor administration reduces renal fibrosis and stabilizes renal function. J Am Soc Nephrol. 2001;12:1448–57.PubMedGoogle Scholar
  141. 141.
    Ferrara N, Davis-Smyth T. The biology of vascular endothelial growth factor. Endocr Rev. 1997;18:4–25.  https://doi.org/10.1210/edrv.18.1.0287.CrossRefPubMedGoogle Scholar
  142. 142.
    Kim YG, et al. Vascular endothelial growth factor accelerates renal recovery in experimental thrombotic microangiopathy. Kidney Int. 2000;58:2390–9.  https://doi.org/10.1046/j.1523-1755.2000.00422.x.CrossRefPubMedGoogle Scholar
  143. 143.
    Leonard EC, Friedrich JL, Basile DP. VEGF-121 preserves renal microvessel structure and ameliorates secondary renal disease following acute kidney injury. Am J Physiol Renal Physiol. 2008;295:F1648–57.  https://doi.org/10.1152/ajprenal.00099.2008.CrossRefPubMedPubMedCentralGoogle Scholar
  144. 144.
    Basile DP, et al. Impaired endothelial proliferation and mesenchymal transition contribute to vascular rarefaction following acute kidney injury. Am J Physiol Renal Physiol. 2011;300:F721–33.  https://doi.org/10.1152/ajprenal.00546.2010.CrossRefPubMedGoogle Scholar
  145. 145.
    Iliescu R, Fernandez SR, Kelsen S, Maric C, Chade AR. Role of renal microcirculation in experimental renovascular disease. Nephrol Dial Transplant. 2010;25:1079–87.  https://doi.org/10.1093/ndt/gfp605.CrossRefPubMedGoogle Scholar
  146. 146.
    Chade AR, Tullos NA, Harvey TW, Mahdi F, Bidwell GL 3rd. Renal therapeutic angiogenesis using a bioengineered polymer-stabilized vascular endothelial growth factor construct. J Am Soc Nephrol. 2016;27:1741–52.  https://doi.org/10.1681/asn.2015040346.CrossRefPubMedGoogle Scholar
  147. 147.
    Ostendorf T, et al. VEGF(165) mediates glomerular endothelial repair. J Clin Invest. 1999;104:913–23.  https://doi.org/10.1172/jci6740.CrossRefPubMedPubMedCentralGoogle Scholar
  148. 148.
    Masuda Y, et al. Vascular endothelial growth factor enhances glomerular capillary repair and accelerates resolution of experimentally induced glomerulonephritis. Am J Pathol. 2001;159:599–608.  https://doi.org/10.1016/s0002-9440(10)61731-2.CrossRefPubMedPubMedCentralGoogle Scholar
  149. 149.
    Shimizu A, et al. Vascular endothelial growth factor165 resolves glomerular inflammation and accelerates glomerular capillary repair in rat anti-glomerular basement membrane glomerulonephritis. J Am Soc Nephrol. 2004;15:2655–65.  https://doi.org/10.1097/01.asn.0000141038.28733.f2.CrossRefPubMedGoogle Scholar
  150. 150.
    Woolard J, et al. VEGF165b, an inhibitory vascular endothelial growth factor splice variant: mechanism of action, in vivo effect on angiogenesis and endogenous protein expression. Cancer Res. 2004;64:7822–35.  https://doi.org/10.1158/0008-5472.can-04-0934.CrossRefPubMedGoogle Scholar
  151. 151.
    Schumacher VA, et al. Impaired glomerular maturation and lack of VEGF165b in Denys-Drash syndrome. J Am Soc Nephrol. 2007;18:719–29.  https://doi.org/10.1681/asn.2006020124.CrossRefPubMedGoogle Scholar
  152. 152.
    Qiu Y, et al. Overexpression of VEGF165b in podocytes reduces glomerular permeability. J Am Soc Nephrol. 2010;21:1498–509.  https://doi.org/10.1681/asn.2009060617.CrossRefPubMedPubMedCentralGoogle Scholar
  153. 153.
    Tanaka T. Expanding roles of the hypoxia-response network in chronic kidney disease. Clin Exp Nephrol. 2016;20:835–44.  https://doi.org/10.1007/s10157-016-1241-4.CrossRefPubMedGoogle Scholar
  154. 154.
    Tanaka T, et al. Cobalt promotes angiogenesis via hypoxia-inducible factor and protects tubulointerstitium in the remnant kidney model. Lab Investig. 2005;85:1292–307.  https://doi.org/10.1038/labinvest.3700328.CrossRefPubMedGoogle Scholar
  155. 155.
    Maxwell PH, Eckardt KU. HIF prolyl hydroxylase inhibitors for the treatment of renal anaemia and beyond. Nat Rev Nephrol. 2016;12:157–68.  https://doi.org/10.1038/nrneph.2015.193.CrossRefPubMedGoogle Scholar
  156. 156.
    Kushida N, et al. Hypoxia-inducible factor-1alpha activates the transforming growth factor-beta/SMAD3 pathway in kidney tubular epithelial cells. Am J Nephrol. 2016;44:276–85.  https://doi.org/10.1159/000449323.CrossRefPubMedGoogle Scholar
  157. 157.
    Basu RK, et al. Interdependence of HIF-1alpha and TGF-beta/Smad3 signaling in normoxic and hypoxic renal epithelial cell collagen expression. Am J Physiol Renal Physiol. 2011;300:F898–905.  https://doi.org/10.1152/ajprenal.00335.2010.CrossRefPubMedPubMedCentralGoogle Scholar
  158. 158.
    Rozen-Zvi B, et al. TGF-beta/Smad3 activates mammalian target of rapamycin complex-1 to promote collagen production by increasing HIF-1alpha expression. Am J Physiol Renal Physiol. 2013;305:F485–94.  https://doi.org/10.1152/ajprenal.00215.2013.CrossRefPubMedPubMedCentralGoogle Scholar
  159. 159.
    Higgins DF, et al. Hypoxic induction of Ctgf is directly mediated by Hif-1. Am J Physiol Renal Physiol. 2004;287:F1223–32.  https://doi.org/10.1152/ajprenal.00245.2004.CrossRefPubMedGoogle Scholar
  160. 160.
    Kroening S, Neubauer E, Wessel J, Wiesener M, Goppelt-Struebe M. Hypoxia interferes with connective tissue growth factor (CTGF) gene expression in human proximal tubular cell lines. Nephrol Dial Transplant. 2009;24:3319–25.  https://doi.org/10.1093/ndt/gfp305.CrossRefPubMedGoogle Scholar
  161. 161.
    Kimura K, et al. Stable expression of HIF-1alpha in tubular epithelial cells promotes interstitial fibrosis. Am J Physiol Renal Physiol. 2008;295:F1023–9.  https://doi.org/10.1152/ajprenal.90209.2008.CrossRefPubMedPubMedCentralGoogle Scholar
  162. 162.
    Higgins DF, et al. Hypoxia promotes fibrogenesis in vivo via HIF-1 stimulation of epithelial-to-mesenchymal transition. J Clin Invest. 2007;117:3810–20.  https://doi.org/10.1172/jci30487.CrossRefPubMedPubMedCentralGoogle Scholar
  163. 163.
    Yu X, et al. The balance of beneficial and deleterious effects of hypoxia-inducible factor activation by prolyl hydroxylase inhibitor in rat remnant kidney depends on the timing of administration. Nephrol Dial Transplant. 2012;27:3110–9.  https://doi.org/10.1093/ndt/gfr754.CrossRefPubMedGoogle Scholar
  164. 164.
    Hill JM, et al. Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. N Engl J Med. 2003;348:593–600.  https://doi.org/10.1056/NEJMoa022287.CrossRefPubMedGoogle Scholar
  165. 165.
    Krenning G, et al. Endothelial progenitor cell dysfunction in patients with progressive chronic kidney disease. Am J Physiol Renal Physiol. 2009;296:F1314–22.  https://doi.org/10.1152/ajprenal.90755.2008.CrossRefPubMedPubMedCentralGoogle Scholar
  166. 166.
    de Groot K, et al. Uremia causes endothelial progenitor cell deficiency. Kidney Int. 2004;66:641–6.  https://doi.org/10.1111/j.1523-1755.2004.00784.x.CrossRefPubMedGoogle Scholar
  167. 167.
    Hung SC, et al. Indoxyl sulfate suppresses endothelial progenitor cell-mediated neovascularization. Kidney Int. 2016;89:574–85.  https://doi.org/10.1016/j.kint.2015.11.020.CrossRefPubMedGoogle Scholar
  168. 168.
    Chade AR, et al. Endothelial progenitor cells restore renal function in chronic experimental renovascular disease. Circulation. 2009;119:547–57.  https://doi.org/10.1161/circulationaha.108.788653.CrossRefPubMedPubMedCentralGoogle Scholar
  169. 169.
    Huang TH, et al. Peripheral blood-derived endothelial progenitor cell therapy prevented deterioration of chronic kidney disease in rats. Am J Transl Res. 2015;7:804–24.PubMedPubMedCentralGoogle Scholar
  170. 170.
    Goligorsky MS, Yasuda K, Ratliff B. Dysfunctional endothelial progenitor cells in chronic kidney disease. J Am Soc Nephrol. 2010;21:911–9.  https://doi.org/10.1681/asn.2009111119.CrossRefPubMedGoogle Scholar
  171. 171.
    Anglani F, et al. In search of adult renal stem cells. J Cell Mol Med. 2004;8:474–87.CrossRefGoogle Scholar
  172. 172.
    Tanaka S, Tanaka T, Nangaku M. Hypoxia and dysregulated angiogenesis in kidney disease. Kidney Dis (Basel). 2015;1:80–9.  https://doi.org/10.1159/000381515.CrossRefGoogle Scholar
  173. 173.
    Kunter U, et al. Mesenchymal stem cells prevent progressive experimental renal failure but maldifferentiate into glomerular adipocytes. J Am Soc Nephrol. 2007;18:1754–64.  https://doi.org/10.1681/asn.2007010044.CrossRefPubMedGoogle Scholar
  174. 174.
    Kramann R, et al. Perivascular Gli1+ progenitors are key contributors to injury-induced organ fibrosis. Cell Stem Cell. 2015;16:51–66.  https://doi.org/10.1016/j.stem.2014.11.004.CrossRefPubMedGoogle Scholar
  175. 175.
    Gregorini M, et al. Mesenchymal stromal cells prevent renal fibrosis in a rat model of unilateral ureteral obstruction by suppressing the renin-angiotensin system via HuR. PLoS One. 2016;11:e0148542.  https://doi.org/10.1371/journal.pone.0148542.CrossRefPubMedPubMedCentralGoogle Scholar
  176. 176.
    Huuskes BM, et al. Combination therapy of mesenchymal stem cells and serelaxin effectively attenuates renal fibrosis in obstructive nephropathy. FASEB J. 2015;29:540–53.  https://doi.org/10.1096/fj.14-254789.CrossRefPubMedGoogle Scholar
  177. 177.
    Eirin A, et al. Adipose tissue-derived mesenchymal stem cells improve revascularization outcomes to restore renal function in swine atherosclerotic renal artery stenosis. Stem Cells. 2012;30:1030–41.  https://doi.org/10.1002/stem.1047.CrossRefPubMedPubMedCentralGoogle Scholar
  178. 178.
    Zhu XY, et al. Mesenchymal stem cells and endothelial progenitor cells decrease renal injury in experimental swine renal artery stenosis through different mechanisms. Stem Cells. 2013;31:117–25.  https://doi.org/10.1002/stem.1263.CrossRefPubMedPubMedCentralGoogle Scholar
  179. 179.
    Imberti B, et al. Renal progenitors derived from human iPSCs engraft and restore function in a mouse model of acute kidney injury. Sci Rep. 2015;5:8826.  https://doi.org/10.1038/srep08826.CrossRefPubMedPubMedCentralGoogle Scholar
  180. 180.
    Toyohara T, et al. Cell therapy using human induced pluripotent stem cell-derived renal progenitors ameliorates acute kidney injury in mice. Stem Cells Transl Med. 2015;4:980–92.  https://doi.org/10.5966/sctm.2014-0219.CrossRefPubMedPubMedCentralGoogle Scholar
  181. 181.
    Chiang CK, Tanaka T, Inagi R, Fujita T, Nangaku M. Indoxyl sulfate, a representative uremic toxin, suppresses erythropoietin production in a HIF-dependent manner. Lab Investig. 2011;91:1564–71.  https://doi.org/10.1038/labinvest.2011.114.CrossRefPubMedGoogle Scholar
  182. 182.
    Asai H, et al. Activation of aryl hydrocarbon receptor mediates suppression of hypoxia-inducible factor-dependent erythropoietin expression by indoxyl sulfate. Am J Physiol Cell Physiol. 2016;310:C142–50.  https://doi.org/10.1152/ajpcell.00172.2015.CrossRefPubMedGoogle Scholar
  183. 183.
    Tanaka T, Yamaguchi J, Higashijima Y, Nangaku M. Indoxyl sulfate signals for rapid mRNA stabilization of Cbp/p300-interacting transactivator with Glu/Asp-rich carboxy-terminal domain 2 (CITED2) and suppresses the expression of hypoxia-inducible genes in experimental CKD and uremia. FASEB J. 2013;27:4059–75.  https://doi.org/10.1096/fj.13-231837.CrossRefPubMedGoogle Scholar
  184. 184.
    Palm F, et al. Uremia induces abnormal oxygen consumption in tubules and aggravates chronic hypoxia of the kidney via oxidative stress. Am J Physiol Renal Physiol. 2010;299:F380–6.  https://doi.org/10.1152/ajprenal.00175.2010.CrossRefPubMedGoogle Scholar
  185. 185.
    Yamaguchi J, Tanaka T, Inagi R. Effect of AST-120 in chronic kidney disease treatment: still a controversy? Nephron. 2017;135:201–6.  https://doi.org/10.1159/000453673.CrossRefPubMedGoogle Scholar
  186. 186.
    Akizawa T, et al. Effect of a carbonaceous oral adsorbent on the progression of CKD: a multicenter, randomized, controlled trial. Am J Kidney Dis. 2009;54:459–67.  https://doi.org/10.1053/j.ajkd.2009.05.011.CrossRefPubMedGoogle Scholar
  187. 187.
    Schulman G, et al. Randomized placebo-controlled EPPIC trials of AST-120 in CKD. J Am Soc Nephrol. 2015;26:1732–46.  https://doi.org/10.1681/asn.2014010042.CrossRefPubMedGoogle Scholar
  188. 188.
    Schulman G, et al. The effects of AST-120 on chronic kidney disease progression in the United States of America: a post hoc subgroup analysis of randomized controlled trials. BMC Nephrol. 2016;17:141.  https://doi.org/10.1186/s12882-016-0357-9.CrossRefPubMedPubMedCentralGoogle Scholar
  189. 189.
    Cha RH, et al. A randomized, controlled trial of oral intestinal sorbent AST-120 on renal function deterioration in patients with advanced renal dysfunction. Clin J Am Soc Nephrol. 2016;11:559–67.  https://doi.org/10.2215/cjn.12011214.CrossRefPubMedPubMedCentralGoogle Scholar
  190. 190.
    Chiang CK, Nangaku M, Tanaka T, Iwawaki T, Inagi R. Endoplasmic reticulum stress signal impairs erythropoietin production: a role for ATF4. Am J Physiol Cell Physiol. 2013;304:C342–53.  https://doi.org/10.1152/ajpcell.00153.2012.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Yosuke Hirakawa
    • 1
  • Tetsuhiro Tanaka
    • 1
  • Masaomi Nangaku
    • 1
  1. 1.Division of Nephrology and EndocrinologyThe University of Tokyo School of MedicineTokyoJapan

Personalised recommendations